Charlien Berghen

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Prostate Cancer

Radical Prostatectomy

Chronic Myeloid Leukemia

Top Venues

BJU international

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Hans Van der Eecken, Steven Joniau, Charlien Berghen, Kato Rans, Gert De Meerleer
The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects. Nutrients 15 (23) (2023)
Gaëtan Devos, Charlien Berghen, Henri Van Eecke, Arthur Vander Stichele, Hendrik Van Poppel, Karolien Goffin, Cindy Mai, Liesbeth De Wever, Maarten Albersen, Wouter Everaerts, Gert De Meerleer, Steven Joniau
Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. Cancers 12 (8) (2020)
Charlien Berghen, Steven Joniau, Annouschka Laenen, Gaetan Devos, Kato Rans, Karolien Goffin, Karin Haustermans, Gert De Meerleer
Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial. Future oncology (London, England) 16 (27) (2020)
Charlien Berghen, Maarten Albersen, Pierre Blanchard, Alberto Bossi, Alberto Briganti, Cesare Cozzarini, Karel Decaestecker, Valérie Fonteyne, Karin Haustermans, Steven Joniau, Daryl Lim Joon, Vincent Khoo, Paul L Nguyen, Piet Ost, Geert Villeirs, Christof Vulsteke, Anthony Zietman, Gert De Meerleer
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU international 124 (1) (2019)
Cédric Draulans, Steven Joniau, Valérie Fonteyne, Louke Delrue, Karel Decaestecker, Wouter Everaerts, Piet Dirix, Laura Van den Bergh, Wouter Crijns, Hans Vandendriessche, Lodewijk Van Wynsberge, Piet Ost, Nicolaas Lumen, Pieterjan Buelens, Karin Haustermans, Charlien Berghen, Gert De Meerleer
Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR research protocols 7 (12) (2018)